A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria

Journal of Pharmaceutical and Biomedical Analysis

Volumn 75, Issue , 2013, Pages 192-198

  Spichty, Rebecca ^a   Balimann, Mirjam ^a   Barman, Jasmin ^a,b   Minder, Elisabeth I ^a  

^a Institute of Laboratory Medicine   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Melanocyte stimulating hormone analogs; Afamelanotide; CAMP; Erythropoietic protoporphyria; Melanocortin 1 receptor; Neutralizing anti drug antibodies

Indexed keywords

AFAMELANOTIDE; ALPHA INTERMEDIN; CYCLIC AMP; MELANOCORTIN 1 RECEPTOR; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANTIBODY DETECTION; ARTICLE; BIOASSAY; BIOLOGICAL ACTIVITY; BLOOD SAMPLING; CANCER CELL CULTURE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ELIMINATION; DRUG RECEPTOR BINDING; ERYTHROPOIETIC PROTOPORPHYRIA; HUMAN; MELANOCYTE; MOUSE; NONHUMAN; PIGMENT CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

ALPHA-MSH; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; CROSS REACTIONS; CYCLIC AMP; DERMATOLOGIC AGENTS; HUMANS; HYPOPIGMENTATION; MELANOCYTES; MICE; MONITORING, IMMUNOLOGIC; OSMOLAR CONCENTRATION; PORPHYRIA, ERYTHROPOIETIC; RECEPTOR, MELANOCORTIN, TYPE 1; RECOMBINANT PROTEINS; SECOND MESSENGER SYSTEMS;

EID: 84871745998     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.11.040     Document Type: Article

References (19)

1. Minder E.I. Afamelanotide: an agonistic analog of alpha-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. Expert Opin. Investig. Drugs 2010, 19:1591-1602.
2. Slominski A., Wortsman J., Luger T., Paus R., Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol. Rev. 2000, 80:979-1020.
3. Slominski A., Tobin D.J., Shibahara S., Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev. 2004, 84:1155-1228.
4. Abdel Malek Z.A., Kreutzfeld K.L., Hadley M.E., Bregman M.D., Hruby V.J., Meyskens F.L. Long-term and residual melanotropin-stimulated tyrosinase activity in S91 melanoma cells is density dependent. In Vitro Cell Dev. Biol. 1986, 22:75-81.
5. Barnetson R.S., Ooi T.K., Zhuang L., Halliday G.M., Reid C.M., Walker P.C., Humphrey S.M., Kleinig M.J. [Nle4-d-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J. Invest. Dermatol. 2006, 126:1869-1878.
6. Harms J., Lautenschlager S., Minder C.E., Minder E.I. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N. Engl. J. Med. 2009, 360:306-307.
7. Minder E.I., Harms J., Lautenschlager S., Schneider-Yin X., Deybac J.C., Minder C.E. A double-blind, randomized, controlled phase III trial of afamelanotide (an -MSH-analogue) in erythropoietic protoporphyria (EPP) - preliminary data on a Swiss cohort of patients and a model to determine efficacy in EPP. Berzelius Symposium 81-Porphyrins and Porphyrias 2009.
8. Haylett A.K., Nie Z., Brownrigg M., Taylor R., Rhodes L.E. Systemic photoprotection in solar urticaria with alpha-melanocyte-stimulating hormone analogue [Nle4-d-Phe7]-alpha-MSH. Br. J. Dermatol. 2011, 164:407-414.
9. Dorr R.T., Lines R., Levine N., Brooks C., Xiang L., Hruby V.J., Hadley M.E. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996, 58:1777-1784.
10. Fetissov S.O., Harro J., Jaanisk M., Jarv A., Podar I., Allik J., Nilsson I., Sakthivel P., Lefvert A.K., Hokfelt T. Autoantibodies against neuropeptides are associated with psychological traits in eating disorders. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14865-14870.
11. Gupta S., Devanarayan V., Finco D., Gunn III G.R., Kirshner S., Richards S., Rup B., Song A., Subramanyam M. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J. Pharm. Biomed. Anal. 2011, 55:878-888.
12. Eberle A. The Melanotropins: Chemistry, Physiology and Mechanisms of Action 1988, Karger, Basel.
13. Vaudry H., Eberle A. The Melanotropic Peptides 1993, New York Academy of Sciences, New York.
14. Seamon K.B., Padgett W., Daly J.W. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:3363-3367.
15. Tang W.J., Hurley J.H. Catalytic mechanism and regulation of mammalian adenylyl cyclases. Mol. Pharmacol. 1998, 54:231-240.
16. Kavitha C., Rajamani K., Vadivel E. Coleus forskohlii: a comprehensive review on morphology, phytochemistry and pharmacological aspects. J. Med. Plants Res. 2010, 4:278-285.
17. Chluba-de T.J., Bagutti C., Wikberg J.S., Chhajlani V., Eberle A.N. Stable expression of the human MSH receptor in a mouse melanoma cell line. J. Recept. Signal. Transduct. Res. 1995, 15:43-53.
18. Chluba-de T.J., Bagutti C., Cotti R., Eberle A.N. Induction of constitutive melanogenesis in amelanotic mouse melanoma cells by transfection of the human melanocortin-1 receptor gene. J. Cell Sci. 1996, 109(Pt 8):2023-2030.
19. Harlow E., Lane D. Antibodies: A Laboratory Manual 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor.